AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-09-28 View volume: 9
Nanobodies (VHH antibody fragments) derived from camelid heavy-chain-only antibodies are the smallest functional antigen-binding domains at ~15 kDa. Their unique structural properties — compact size, convex paratope, and exceptional stability — open engineering possibilities unavailable to conventional antibodies. This guide covers the key nanobody engineering strategies, from affinity maturation to multivalent formatting.
Conventional antibodies bind antigen through six CDR loops distributed across a VH–VL heterodimer. Nanobodies achieve binding with just three CDR loops on a single VHH domain. To compensate for the missing VL, nanobodies have evolved distinctive features: an elongated CDR3 loop (often 15–25 residues, compared to 10–15 in human VH) that can insert into enzyme active sites, receptor clefts, and other recessed epitopes inaccessible to flat paratopes; hydrophilic amino acid substitutions at positions that form the VH–VL interface in conventional antibodies (V37F/G, G44E, L45R, W47G), preventing aggregation of the now-exposed surface; and a conserved disulfide bond between CDR1 and CDR3 (in many nanobodies) that rigidifies the extended CDR3 loop architecture.
Initial nanobody hits from immunized libraries or naive/synthetic libraries may need affinity improvement to achieve therapeutic-grade KD values. Common approaches include:
| Strategy | Approach | Typical Improvement |
|---|---|---|
| CDR-targeted mutagenesis | Randomize CDR1 and CDR2 positions while fixing CDR3 (the primary specificity determinant) | 10–100-fold KD improvement |
| Error-prone PCR | Random mutagenesis across the entire VHH, followed by stringent selection | 5–50-fold |
| Structure-guided design | Introduce mutations at computationally predicted contact residues based on docking models | Rational but variable; best combined with screening |
| Ribosome / yeast display | In vitro display systems that enable multiple rounds of selection at decreasing antigen concentration | 100–1,000-fold (iterative rounds) |
Affinity maturation should be confirmed by SPR kinetic measurement rather than ELISA endpoint titers alone. KD improvement can arise from faster association (higher ka) or slower dissociation (lower kd); for therapeutic applications, a slower off-rate is generally more valuable because it extends target residence time in vivo.
A monomeric 15 kDa nanobody is cleared renally within hours, so therapeutic applications require half-life extension and often multivalency. Formatting strategies include:
• Fc fusion (VHH-Fc): A nanobody fused to a human IgG1 Fc creates a ~80 kDa bivalent molecule with FcRn-mediated half-life extension (~2–3 weeks). This format also enables effector functions (ADCC, CDC) if desired.
• Albumin-binding nanobody fusion: Appending an anti-albumin VHH extends half-life by piggybacking on albumin’s FcRn recycling. This approach, used in caplacizumab’s follow-on molecules, avoids Fc-mediated effector functions entirely.
• PEGylation: Chemical attachment of polyethylene glycol (PEG) chains increases hydrodynamic radius above the renal filtration threshold. Effective but adds manufacturing complexity and potential anti-PEG immunogenicity.
• Multivalent / multispecific tandem: Two or three VHH domains linked in series create bispecific or trispecific constructs (30–45 kDa) that retain the compact, modular architecture unique to nanobodies. Linker length and flexibility between domains can be tuned to optimize simultaneous binding.
• Bivalent nanobody: Linking two copies of the same VHH creates an avidity effect, improving apparent affinity by 10–100-fold for multimeric targets (e.g., viral capsid proteins).
Despite high sequence homology to human VH3 family germlines (~80–90%), camelid-origin nanobodies contain framework residues that differ from human sequences and could potentially elicit anti-drug antibody responses. Humanization of nanobodies follows similar principles to conventional antibody humanization: grafting CDRs onto a human VH3 framework scaffold while retaining VHH-specific hallmark residues that are critical for stability and solubility (positions 37, 44, 45, 47). Over-humanization of these hallmark positions can cause aggregation, loss of expression yield, or reduced thermal stability. The balance between immunogenicity risk and biophysical properties must be evaluated case by case, guided by both in silico T-cell epitope prediction and experimental stability data.
• Cryptic epitope access: GPCRs, ion channels, and enzyme active sites with recessed or cleft-shaped epitopes that conventional antibodies cannot reach.
• Intracellular targets: Nanobodies can be expressed intracellularly (intrabodies) for research and potential gene-therapy applications, enabled by their single-domain fold that does not require disulfide bond formation for stability.
• Imaging and diagnostics: Rapid tissue penetration and fast blood clearance produce high-contrast images within hours of injection, ideal for same-day PET/SPECT imaging.
• Inhaled and oral delivery: Exceptional thermostability (Tm often >65°C) and resistance to proteolysis make nanobodies candidates for mucosal delivery routes where conventional antibodies degrade.
• Modular multispecific building blocks: Small size and independent folding make VHHs ideal building blocks for bispecific and trispecific constructs with manageable molecular weight and low aggregation risk.
Need nanobody discovery or engineering? AtaGenix provides end-to-end VHH nanobody development including immunized library construction, phage display screening, affinity maturation, and therapeutic formatting.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-65523339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
